Π‘ΡΠΈΠΌΡΠ»ΡΡΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΡΠΏΡΠ΅ΡΡΠΎΡΠ° p53 ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ΠΎΠΌ Π°Π»ΡΡΠ°
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ, ΠΏΠΎΠΆΠ°Π»ΡΠΉ, Π½ΠΈ ΠΎΠ΄ΠΈΠ½ Π±Π΅Π»ΠΎΠΊ Π½Π΅ ΠΈΠ·ΡΡΠ°Π»ΡΡ ΡΠ°ΠΊ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎ, ΠΊΠ°ΠΊ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΉ ΡΡΠΏΡΠ΅ΡΡΠΎΡ Ρ53. ΠΠ° ΡΡΠ΅ΡΡ Π²Π΅ΠΊΠ° Ρ ΠΌΠΎΠΌΠ΅Π½ΡΠ° Π΅Π³ΠΎ ΠΎΡΠΊΡΡΡΠΈΡ Ρ53 Π±ΡΠ»ΠΎ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ΠΎ Π±ΠΎΠ»Π΅Π΅ 50 ΡΡΡΡΡ Π½Π°ΡΡΠ½ΡΡ ΡΠ°Π±ΠΎΡ, ΠΈ ΠΈΡ ΡΠΈΡΠ»ΠΎ Π½Π΅ΡΠΊΠ»ΠΎΠ½Π½ΠΎ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°Π΅Ρ ΡΠ°ΡΡΠΈ. ΠΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΊ Ρ53 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ, ΠΏΡΠ΅ΠΆΠ΄Π΅ Π²ΡΠ΅Π³ΠΎ, ΡΠ΅ΠΌ, ΡΡΠΎ ΠΎΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠΎΠΌ ΠΊΠ»Π΅ΡΠΊΠΈ, ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ Π°ΠΊΡΠΈΠ²ΠΈΡΡΠ΅ΡΡΡ Π² ΠΎΡΠ²Π΅Ρ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΡΠ»ΠΎΠ²Π½ΡΡ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½ΠΈΠΉ
- ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅
- 1. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ° ΠΈ Π³ΠΈΡΡΠΎΠ½ Π1. ΠΡ
Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΈ ΡΠΎΠ»Ρ Π² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ Ρ53-Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΈ (ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ)
- 1. 1. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ°
- 1. 1. 1. Π‘ΡΡΡΠΊΡΡΡΠ° ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°
- 1. 1. 2. ΠΠ½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°
- 1. 1. 3. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ° ΠΈ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ΅ Π΄Π΅Π»Π΅Π½ΠΈΠ΅
- 1. 1. 4. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ° ΠΈ Π°ΠΏΠΎΠΏΡΠΎΠ·
- 1. 1. 5. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ° ΠΊΠ°ΠΊ ΠΏΠ΅ΡΠ΅ΠΊΠ»ΡΡΠ°ΡΠ΅Π»Ρ Π½Π΅ΠΊΡΠΎΠ·Π° Π½Π° Π°ΠΏΠΎΠΏΡΠΎΠ·
- 1. 1. 6. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ° ΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²Π°Ρ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡ
- 1. 1. 7. ΠΠ°Π½Π½ΡΠ΅ ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠΈ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ° Π½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½ΠΎΠ²
- 1. 2. ΠΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΡΡΠΏΡΠ΅ΡΡΠΎΡ Ρ
- 1. 2. 1. Π‘ΡΡΡΠΊΡΡΡΠ° Ρ
- 1. 2. 2. ' Π Π΅Π³ΡΠ»ΡΡΠΈΡ ΡΡΠΎΠ²Π½Ρ ΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ53 Π² ΠΊΠ»Π΅ΡΠΊΠ΅
- 1. 2. 3. Π‘ΡΠ±ΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ Ρ53. Π ΠΎΠ»Ρ ΠΏΠΎΡΡΡΡΠ°Π½ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ Π²ΠΎ Π²Π½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅ Ρ
- 1. 2. 4. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ53 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΠΠ΅Π¬Π°
- 1. 3. ΠΠΈΡΡΠΎΠ½ Π
- 1. 3. 1. ΠΠΈΡΡΠΎΠ½ Π1. Π‘ΡΡΡΠΊΡΡΡΠ° ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ
- 1. 3. 2. ΠΠΈΡΡΠΎΠ½ Π1 ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈ ΡΠ΅Π³ΡΠ»ΠΈΡΡΠ΅Ρ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΡ
- 1. 3. 3. ΠΠΈΡΡΠΎΠ½ Π1 ΠΈ Ρ
- 1. 3. 4. ΠΠΈΡΡΠΎΠ½ Π1 ΠΈ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ°
- 1. 1. ΠΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ Π°Π»ΡΡΠ°
- 2. 1. Π Π΅Π°ΠΊΡΠΈΠ²Ρ ΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ
- 2. 2. ΠΠ±ΡΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ
- 2. 3. ΠΠ°Π½ΠΈΠΏΡΠ»ΡΡΠΈΠΈ Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 4. ΠΠΎΠ½ΡΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄
- 2. 5. ΠΠ°Π½ΠΈΠΏΡΠ»ΡΡΠΈΠΈ Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΠΌΠ»Π΅ΠΊΠΎΠΏΠΈΡΠ°ΡΡΠΈΡ
- 2. 6. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ Ρ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°
- 2. 7. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°
- 2. 8. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Π³ΠΈΡΡΠΎΠ½Π° Π1, Ρ53 ΠΈ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°
- 2. 9. ΠΠΌΠΌΡΠ½ΠΎΠΏΡΠ΅ΡΠΈΠΏΠΈΡΠ°ΡΠΈΡ Ρ ΡΠΎΠΌΠ°ΡΠΈΠ½Π° (Π‘Π«Π )
- 2. 10. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΠΈ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΎΠ²
- 2. 11. ΠΠ¦Π Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ
- 3. 1. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ° Π½Π° ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΡΠΏΡΠ΅ΡΡΠΎΡΠ° Ρ
- 3. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΡΠΏΡΠ΅ΡΡΠΎΡΠ° Ρ53 ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ΠΎΠΌ Π°Π»ΡΡΠ°
- 3. 3. ΠΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ Π΄Π΅ΡΠ΅ΡΠΌΠΈΠ½Π°Π½Ρ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ°, ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΡΡ Π·Π° Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Ρ
- 3. 4. Π ΠΎΠ»Ρ Π³ΠΈΡΡΠΎΠ½Π° Π1 Π² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ53 ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½ΠΎΠΌ Π°Π»ΡΡΠ°
- 3. 5. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΠΈΡΠΎΠ·ΠΈΠ½ΠΎΠ²ΠΎΠΉ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ 1ΠΠ1 Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΡΠΎΠ²Π½Ρ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π° Π°Π»ΡΡΠ° Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΠΠ΅Π¬Π°
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Haritos A.A., Goodall G.J., Horecker B.L. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.// Proc. Natl. Acad. Sci. USA. -1984-V. 81 -P. 1008−1111.
- Pineiro A., Cordero O.J., Nogueira M. Fifteen years of prothymosin alpha: contradictory past and new horizons.// Peptides. 2000 — V. 21 — P. 1433.
- Vartapetian A.B., Uversky V.N. Prothymosin alpha: a simple yet mysterious protein.// Protein structures: kaleidoscope of structural properties and functions. India, Research Signpost.
- Goodall G.J., Dominguez F., Horecker B.L. Molecular cloning of cDNA for human prothymosin alpha.// Proc. Natl. Acad. Sci. USA. 1986 — V. 83 — P. 8926−8928.
- Eschenfeldt W.H., Berger S.L. The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA.// Proc. Natl. Acad. Sci. USA. 1986 — V. 83 — P. 9403−9407.
- Eschenfeldt W.H., Manrow R.E., Krug M.S., Berger S.L. Isolation and partial sequencing of the human prothymosin alpha gene family. Evidence against export of the gene products.// J. Biol. Chem. 1989 — V. 264 — P. 7546−7555.
- Aniello F., Branno M., De Rienzo G., Ferrara D., Palmiero C., Minucci S. First evidence of prothymosin alpha in a non-mammalian vertebrate and its involvement in the spermatogenesis of the frog Rana esculenta.// Mech. Dev. 2002 — V. 110 — P. 213−217.
- Gast K., Damaschun H., Eckert K., Schulze-Forster K., Maurer H.R., Muller-Frohne M., Zirwer D., Czarnecki J., Damaschun G. Prothymosin alpha: a biologically active protein with random coil conformation.// Biochemistry. 1995 — V.34 — P. 3211−3218.
- Uversky V.N., Gillespie J.R., Fink A.L. Why are «natively unfolded» proteins unstructured under physiologic conditions?// Proteins. 2000 — V. 41 — P. 415−427.
- Abiko T., Sekino H. Synthesis of an immunologically active fragment analog of prothymosin alpha with enhanced enzymatic stability.// Chem. Pharm. Bull. (Tokyo). 1991 — V. 39 — P. 752−756.
- Bachmair A., Finley D., Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue.// Science. 1986 — V. 234 — P. 179−186.
- Sburlati A.R., De La Rosa A., Batey D.W., Kurys G.L., Manrow R.E., Pannell L.K., Martin B.M., Sheeley D.M., Berger S.L. Phosphorylation of human and bovine prothymosin alpha in vivo.// Biochemistry. 1993 — V. 32 — P. 4587−4596.
- Tsitsiloni O.E., Yialouris P.P., Sekeri-Pataryas K., Haritos A.A. Prothymosin alpha is not a nuclear polypeptide.// Experientia. 1989 — V. 45 — P. 332−334.
- Gomez-Marquez J., Segade F. Prothymosin alpha is a nuclear protein.// FEBS Lett. 1988 -V. 226-P. 217−219.
- Watts J.D., Cary P.D., Crane-Robinson C. Prothymosin alpha is a nuclear protein.// FEBS Lett. 1989 — V. 245 — P. 17−20.
- Watts J.D., Cary P.D., Sautiere P., Crane-Robinson C. Thymosins: both nuclear and cytoplasmic proteins.// Eur. J. Biochem. 1990 — V. 192 — P. 643−651.
- Robbins J., Dilworth S.M., Laskey R.A., Dingwall C. Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence.// Cell. 1991 — V. 64 — P. 615−623.
- Palvimo J., Linnala-Kankkunen A. Identification of a low-Mr acidic nuclear protein as prothymosin alpha.// FEBS Lett. 1990 — V. 277 — P. 257−260.
- Enkemann S.A., Ward R.D., Berger S.L. Mobility within the nucleus and neighboring cytosol is a key feature of prothymosin-alpha.// J Histochem. Cytochem. 2000 — V. 48 — P. 13 411 355.
- Wang J., Shiels C., Sasieni P., Wu P.J., Islam S.A., Freemont P. S., Sheer D. Promyelocyte leukemia nuclear bodies associate with transcriptionally active genomic regions.// J. Cell. Biol. 2004 — V. 164 — P. 515−526.
- Clinton M., Frangou-Lazaridis M., Panneerselvam C., Horecker B.L. Prothymosin alpha and parathymosin: rhRNA and polypeptide levels in rodent tissues.// Arch. Biochem. Biophys. -1989-V. 269-P. 256−263.
- Frillingos S., Tsolas O. Age- and sex-related differences in the content of prothymosin alpha in rat tissues.// Experientia. 1992 — V. 48 — P. 236−239.
- Roson E., Garcia-Caballero G., Heimer E.P., Felix A.M., Dominguez F. Cellular distribution of prothymosin alpha and parathymosin in rat thymus and spleen.// J. Histochem. Cytochem. -1990-V. 38-P. 1889−1894.
- Roson E., Gallego R., Garcia-Caballero T., Heimer E.P., Felix A.M., Dominguez F. Prothymosin alpha expression is associated to cell division in rat testis.// Histochemistry. -1990-V. 94-P. 597−599.
- Garcia-Caballero T., Dominguez F., Roson E., Gallego R., Zalvide J., Forteza J., Beiras A. Distribution of prothymosin alpha in rat and human adrenal cortex.// Anat. Rec. 1994 — V. 239 — P. 88−94.
- Gomez-Marquez J., Segade F., Dosil M., Pichel J.G., Bustelo X.R., Freire M. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation.// J. Biol. Chem. 1989 — V. 264 — P. 8451−8454.
- Dosil M., Freire M., Gomez-Marquez J. Tissue-specific and differential expression of prothymosin alpha gene during rat development.// FEBS Lett. 1990 — V. 269 — P. 373−376.
- Bustelo X.R., Otero A., Gomez-Marquez J., Freire M. Expression of the rat prothymosin alpha during T-Lymphocyte proliferation and liver regeneration.// J. Biol. Chem. 1991 — V. 266 — P. 1443−1447.
- Mori M., Barnard G.F., Staniunas R.J., Jessup J.M., Steele G.D.Jr., Chen L.B. Prothymosin alpha mRNA expression correlates with that of c-myc in human colon cancer.// Oncogene. -1993 -V. 8-P. 2821−2826.
- Magdalena C., Dominguez F., Loidi L., Puente J.L. Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer.// Br. J. Cancer. — 2000 V. 82 — P. 584 590.
- Mitani M., Kuwabara Y., Kawamura H., Sato A., Hattori K., Fujii Y. Significance of plasma thymosin alphal measurements in gastric cancer patients.// World J. Surg. 2000 — V. 24 — P. 455−458.
- Wu C.G., Habib N.A., Mitry R.R., Reitsma P.H., van Deventer S.J., Chamuleau R.A. Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma.// Br. J. Cancer. 1997 — V. 76 — P. 1199−1204.
- Sasaki H., Nonaka M., Fujii Y., Yamakawa Y., Fukai I., Kiriyama M., Sasaki M. Expression of the Prothymosin a as a Prognostic Factor in Lung Cancer.// Surg. Today. 2001 — V. 31 -P. 936−938. β’
- Sburlati A.R., Manrow R.E., Berger S.L. Prothymosin alpha antisense oligomers inhibit myeloma cell division.// Proc. Natl. Acad. Sci. USA. 1991 — V. 88 — P. 253−257.
- Rodriguez P., Vinuela J.E., Alvarez-Fernandez L., Gomez-Marquez J. Prothymosin alpha antisense oligonucleotides induce apoptosis in HL-60 cells.// Cell. Death. Differ. 1999 — V. 6 -P. 3−5.
- Rodriguez P., Vinuela J.E., Alvarez-Fernandez L., Buceta M., Vidal A., Dominguez F., Gomez-Marquez J. Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells.// Biochem. J. 1998 — V. 331 — P. 753−761.
- Evstafieva A.G., Belov G.A., Kalkum M., Chichkova N.V., Bogdanov A.A., Agol V.I., Vartapetian A.B. Prothymosin alpha fragmentation in apoptosis.// FEBS Lett. 2000 — V. 467 -P. 150−154.
- Evstafieva A.G., Chichkova N.V., Makarova T.N., Vartapetian A.B., Vasilenko A.V., Abramov V.M., Bogdanov A.A. Overproduction in Escherichia coli, purification and properties of human prothymosin alpha.// Eur. J. Biochem. — 1995 V. 231 — P. 639−643.
- Jiang X., Kim H.E., Shu H., Zhao Y., Zhang H., Kofron J., Donnelly J., Burns D., Ng S.C., Rosenberg S., Wang X. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.// Science. 2003 — V. 299 — P. 223−226.
- Qi X., Wang L., Du F. Novel small molecules relieve prothymosin a-mediated inhibition of apoptosome formation by blocking its interaction with Apaf-1.// Biochemistry. 2010 — V. 49 -P. 1923−1930.
- Kim H.E., Du F., Fang M., Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1.// Proc. Natl. Acad. Sci. USA. 2005 — V. 102 — P. 17 545−17 550.
- Lai A., Kawai T., Yang X., Mazan-Mamczarz K., Gorospe M. Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha.// EMBO J. 2005 — V. 24 — P. 1852−1862.
- Ueda H., Fujita R., Yoshida A., Matsunaga H., Ueda M. Identification of prothymosin-alphal, the necrosis-apoptosis switch molecule in cortical neuronal cultures.// J. Cell. Biol. 2007 -V. 176-P. 853−862.
- Fujita R., Ueda H. Prothymosin-alphal prevents necrosis and apoptosis following stroke.// Cell. Death. Differ. 2007 — V. 14 — P. 1839−1842.
- Fujita R., Ueda M., Fujiwara K., Ueda H. Prothymosin-a plays a defensive role in retinal ischemia through necrosis and apoptosis inhibition.// Cell. Death. Differ. 2009 — V. 16 — P. 349−358.
- Fujita R, Ueda H. Protein kinase C-mediated cell death mode switch induced by high glucose.// Cell. Death. Differ. 2003 — V. 10 — P. 1336−1347.
- Matsunaga H., Ueda H. Stress-induced non-vesicular release of prothymosin-a initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage.// Cell. Death. Differ. -2010-V. 17-P. 1760−1772.
- Orre R.S., Cotter M.A., Subramanian C., Robertson E.S. Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro.// J. Biol. Chem. -2000-V. 17-P. 1794−1799.
- Letsas K.P., Frangou-Lazaridis M., Skyrlas A. s Tsatsoulis A., Malamou-Mitsi V. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.// Pathol. Int. 2005 — V. 55 — P. 694−702.
- Sasaki H., Sato Y., Kondo S., Fukai I., Kiriyama M., Yamakawa Y., Fujii Y. Expression of the prothymosin alpha mRNA correlated with that of N-myc in neuroblastoma.// Cancer Lett. -2001 -V. 168-P. 191−195.
- Li K. J, Shiau A.L., Chiou Y.Y., Yo Y.T., Wu C.L. Prothymosin a overexpression induces polycystic kidney disease.// Kidney Int. 2005 — V. 67 — P. 1710−1722.
- ΠΠΎΠΏΠ½ΠΈΠ½ Π.Π. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π°.// ΠΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ" Π.: Π ΠΠ‘, 2004. — Π‘. 34−53.
- Cotter Π. Π, Robertson E.S. Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.// Mol. Cell. Biol. — 2000-V. 20-P. 5722−5735.
- Allday M.J., Farrell P.J. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 inGl-arrested cells.// J. Virol. 1994 — V. 68 — P. 34 913 498.
- Karetsou Z., Kretsovali A., Murphy C., Tsolas O., Papamarcaki T. Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription.// EMBO Rep. 2002 -V. 3 — P. 361−366.
- Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development.// Genes. Dev. 2000 — V. 14 — P. 1553−1577.
- Hartzog G.A., Winston F. Nucleosomes and transcription: recent lessons from genetics.// Curr. Opin. Genet. Dev. 1997 — V. 7 — P. 192−198.
- Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., Eck M.J. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha.// Proc. Natl. Acad. Sci. USA. 2002 — V. 99 — P. 5367−5372.
- Knight J.S., Lan K., Subramanian C., Robertson E.S. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines.// J. Virol. 2003 — V. 77 — P. 4261−4272.
- Xue F., Cooley L. Kelch encodes a component of intercellular bridges in Drosophila egg chambers.// Cell. 1993 — V. 72 — P. 681−693.
- Kang M.L., Kobayashi A., Wakabayashi N., Kim S.G., Yamamoto M. Scaffolding of Keapl to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes.// Proc. Natl. Acad. Sci. USA. 2004 — V. 101 — P. 2046−2051.
- Zhang D.D., Hannink M. Distinct cysteine residues in Keapl are required for Keapl-dependent ubiquitination of Nr?2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress.// Mol. Cell. Biol. 2003 — V. 23 — P. 8137−8151.
- Itoh Π., Wakabayashi N., Katoh Y., Ishii Π’., Igarashi K" Engel J.D., Yamamoto M. Keapl. repress nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.// Genes Develop. 1999 — V. 13 — P. 76−86.
- ΠΠ΅Π»ΡΠ½ΠΈΠΊΠΎΠ² C.B. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠΌΠΎΠ·ΠΈΠ½Π°, Π° Ρ Π°Π΄Π°ΠΏΡΠ΅ΡΠΎΠΌ ΡΠ±ΠΈΠΊΠ²ΠΈΡΠΈΠ½-Π»ΠΈΠ³Π°Π·Ρ Π±Π΅Π»ΠΊΠΎΠΌ Keapl: ΠΠ²ΡΠΎΡΠ΅Ρ. Π΄ΠΈΡ. ΠΊΠ°Π½Π΄. Ρ ΠΈΠΌ. ΠΠ°ΡΠΊ. Π., 2008. -19Ρ.
- Niture S.K., Jaiswal Π.Π. Prothymosin-alpha mediates nuclear import of the INrf2/CuI3 Rbxl complex to degrade nuclear Nrf2.// J. Biol. Chem. 2009 -V. 284(20) — P. 13 856−13 868.
- Johnson R.A., Ince T.A., Scotto K.W. Transcriptional repression by p53 through direct binding to a novel DNA element.// J. Biol. Chem. 2001 — V. 276 — P. 27 716−27 720.
- Attardi L.D., DePinho R.A. Conquering the complexity of p53.// Nature Genetics 2004 — V. 36-P. 7−8.
- Romer L., Klein C., Dehner A., Kessler H., Buchner J. p53 a natural cancer killer: structural insights and therapeutic concepts.// Angew Chem. Int. Ed. Engl. — 2006 — V. 45(39) — P. 6440−6460.
- Scoumanne A., Harms K.L., Chen X. Structural basis for gene activation by p53 family members.// Cancer Biol. Ther. 2005 — V. 4(11) — P. 1178−1185.
- Harms K.L., Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties.// Cell. Death. Differ. 2006 — V. 13(6) — P. 890−897.
- Kubbutat M.H., Ludwig R.L., Ashcroft M., Vousden K.H. Regulation of Mdm2-directed degradation by the Π‘ terminus of p53.// Mol. Cell Biol. 1998 — V. 18 — P. 5690−5698.
- Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53.// Nature. 1997 — V. 387 — P. 296−299.
- Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2.// Nature. -1997-V. 387-P. 299−303.
- Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.// J. Biol. Chem. 2000 — V. 275 — P. 8945−8951.
- Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.// Oncogene. 2000 — V. 19 — P. 1473−1476.
- Siepe D., Jentsch S. Prolyl isomerase Pinl acts as a switch to control the degree of substrate ubiquitylation.// Nat. Cell. Biol. 2009 — V. 11 — P. 967−972.
- Barak Y., Juven Π’., Haffher R., Oren M. Mdm2 expression is induced by wild type p53 activity.// EMBO J. 1993 — V. 12 — P. 461−468.
- Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop.// Genes Dev. 1993 — V. 7 — P. 1126−1132.
- Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.// Cell. 1997 — V. 91 — P. 325−334.
- Shieh S.Y., Taya Y., Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.// EMBO J. 1999 — V. 18 — P. 1815−1823.
- Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade.// Genes. Dev. 1998-V. 12-P. 2831−2841.
- Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.// Mol. Cell. Biol. 1999 — V. 19 — P. 1202−1209.
- Xu Y. Regulation of p53 responses by post-translational modifications.// Cell. Death. Differ. -2003-V. 10-P. 400−403.
- Vousden K.H. Outcomes of p53 activation-spoilt for choice.// J. Cell. Sci. — 2006 V. 119(24)-P. 5015−5020.107. zur Hausen H. Viruses in human cancers.// Science. 1991 — V. 254(5035) — P. 1167−1173.
- Werness B.A., Levine A. J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53.// Science. 1990 — V. 248(4951) — P. 76−79.
- Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.// EMBO J. 1989 V. 8 — P. 3905−3910.
- Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human ceratinocytes.// J. Virol. 1989 — V. 63 — P. 4417−4421.
- Schneider-Gadicke A., Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes.// EMBO J. 1986 — V. 5 -P. 2285−2292.
- Vogelstein B., Kinzler K.W. p53 function and dysfunction.// Cell. 1992 — V. 70(4) — P. 523 526.
- Scheffner M., Whitaker N.J. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system.// Semin. Cancer Biol. 2003 — V. 13 — P. 59−67.
- Huibregtse J.M., Scheffner M., Beaudenon S., Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase.// Proc. Natl. Acad. Sci. USA -1995) V. 92 — P. 2563−2567.
- Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins.// Mol. Cell. Biol. 1993 — V. 13 — P. 4918−4927.
- Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.// Proc. Natl. Acad. Sci. USA 2001 — V. 98 — P. 1218−1223.
- Munger K., Basile J.R., Duensing S., Eichten A., Gonzales S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein.// Oncogene. 2001 — V. 20 — P. 7888−7898.
- Boyer S.N., Wazer D.E., Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through through ubiquitin-proteasome pathway.// Cancer. Res. -1996 V. 56 — P. 4620−4624.
- Wang J., Sampath A., Raychaudhuri P., Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.// Oncogene. 2001 -V. 20-P. 4740−4749.
- Stevaux O., Dyson NJ. A revised picture of the E2 °F transcriptional network and RB function.// Curr. Opin. Cell. Biol. 2002 — V. 14 — P. 684−691.
- Longworth M.S., Laimins L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protien are essential for the life cycle of human papillomavirus type 31.// J. Virol. 2004 — V. 78 — P. 3533−3541.
- Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome.// Cell. 1999 — V. 98(3) — P. 285−294.
- Luger K., Richmond T.J. The histone tails of the nucleosome.// Curr. Opin. Genet. Dev. -1998-V. 8(2)-P. 140−146.
- Workman J.L., Kingston R.E. Alteration of nucleosome structure as a mechanism of transcriptional regulation.// Annu. Rev. Biochem. 1998 — V. 67 — P. 545−79.
- Bustin M., Catez F., Lim J. The dynamics of histone HI function in chromatin.// Molecular Cell. 2005 — V. 17 — P. 617−620.
- Parseghian M.H., Hamkalo B.A. A compendium of the histone HI family ofsomatic subtypes: An elusive cast of characters and their characteristics.// Biochem. Cell. Biol. 2001 — V. 79 -P.289−304.
- Ponte I., Vila R., Suau P. Sequence complexity of histone HI subtypes.// Mol. Biol. Evol. -2003 V. 20(3) — P. 371−380.
- Khochbin S. Histone HI diversity: bridging regulatory signals to linker histone function.// Gene. 2001. V. 271(1)-P. 1−12.
- Vignali M., Workman J.L. Location and function of linker histones.// Nat. Struct. Biol. 1998 -V. 5(12)-P. 1025−1028.
- Thomas J.O. Histone HI: location and role.// Curr. Opin. Cell. Biol. 1999 — V. 11(3) — P. 312−317.
- Lusser A., Kadonaga J.T. Strategies for the reconstitution of chromatin.// Nat. Methods. -2004-V. 1(1)-P. 19−26.
- Thoma F., Koller T., Klug A. Involvement of histone HI in the organization of the nucleosome and of the salt-dependent superstructures of chromatin.// J. Cell. Biol. 1979 — V. 83-P. 403−427.
- Pennings S., Meersseman G., Bradbury E.M. Linker histones HI and H5 prevent the mobility of positioned nucleosomes.// Proc. Natl. Acad. Sci. USA. 1994 — V. 91(22) — P. 1 027 510 279.
- Shimamura A., Sapp M., Rodriguez-Campos A., Worcel A. Histone HI represses transcription from minichromosomes assembled in vitro.// Mol. Cell. Biol. 1989 -V. 9(12) -P. 5573−5584.
- Laybourn P.J., Kadonaga J.T. Role of nucleosomal cores and histone HI in regulation of transcription by RNA polymerase II.// Science. 1991 — V. 254(5029) — P. 238−245.
- Brown, D.T., Alexander, B.T., Sittman, D.B. Differential effect of HI variant overexpression on cell cycle progression and gene expression.// Nucleic Acid Res. 1996 V. 24 — P. 486−493.
- Shen X., Gorovsky M.A. Linker histone HI regulates specific gene expression but not global transcription in vivo.// Cell. 1996 — V. 86 — P. 475−483.
- Ni J.Q., Liu L.P., Hess D., Rietdorf J., Sun F.L. Drosophila ribosomal proteins are associated with linker histone HI and suppress gene transcription.// Genes. Dev. 2006 — V. 20(14) — P. 1959−1973.
- Shen X., Yu L., Weir J.W., Gorovsky M.A. Linker histones are not essential and affect chromatin condensation in vivo.// Cell. 1995 — V. 82(1) — P. 47−56.
- Ushinsky S.C., Bussey H., Ahmed A.A., Wang Y., Friesen J., Williams B.A., Storms R.K. Histone HI in Saccharomyces cerevisiae.// Yeast. 1997 — V. 13(2) — P. 151−161.
- Patterton H.G., Landel C.C., Landsman D., Peterson C.L., Simpson R.T. The biochemical and phenotypic characterization of Hholp, the putative linker histone HI of Saccharomyces cerevisiae.// J. Biol. Chem. 1998 — V. 273(13) — P. 7268−7276.
- Ramon A., Muro-Pastor M.I., Scazzocchio C., Gonzalez R. Deletion of the unique gene encoding a typical histone HI has no apparent phenotype in Aspergillus nidulans.// Mol. Microbiol. 2000 — V. 35(1) — P. 223−233.
- Rupp R.A., Becker P.B. Gene regulation by histone HI: new links to DNA methylation.// Cell. 2005 — V. 123(7) — P. 1178−1179.
- Kim K., Choi J., Heo K., Kim H., Levens D., Kohno K., Johnson E.M., Brock H.W., An W. Isolation and characterization of a novel HI.2 complex that acts as a repressor of p53-mediated transcription.// J. Biol. Chem. 2008 — V. 283(14) — P. 9113−9126.
- Nishiyama M., Nakayama K., Tsunematsu R., Tsukiyama T., Kikuchi A., Nakayama K.I. Early embryonic death in mice lacking the beta-catenin-binding protein Duplin.// Mol. Cell. Biol. 2004 — V. 24(19) — P. 8386−8394.
- An W., Palhan V.B., Karymov M.A., Leuba S.H., Roeder R.G. Selective requirements for histone H3 and H4 N termini in p300-dependent transcriptional activation from chromatin.// Mol. Cell. 2002 — V. 9(4) — P. 811−821.
- Papamarcaki T., Tsolas O. Prothymosin alpha binds to histone HI in vitro.// FEBS Lett. — 1994-V. 345 -P. 71−75.
- Diaz-Jullien C., Perez-Estevez A., Covelo G., Freire M. Prothymosin alpha binds histones in vitro and shows activity in nucleosome assembly assay.// Biochim. Biophys. Acta. 1996 — V. 1296 — P. 219−227.
- Karetsou Z., Sandaltzopoulos R., Frangou-Lazaridis M., Lai C.Y., Tsolas O., Becker P.B., Papamarcaki T. Prothymosin alpha modulates the interaction of histone HI with chromatin.// Nucleic Acids Res. 1998 — V. 26 — P. 3111−3118.
- Gomez-Marquez J., Rodriguez P. Prothymosin alpha is a chromatin-remodelling protein in mammalian cells.// Biochem. J. 1998 — V. 333 — V. 1−3.
- Karetsou Z., Martic G., Tavoulari S., Christoforidis S., Wilm M., Gruss C., Papamarcaki T. Prothymosin alpha associates with the oncoprotein SET and is involved in chromatin decondensation.// FEBS Lett. 2004 — V. 577 — P. 496−500.
- Martic G., Karetsou Z., Kefala K., Politou A.S., Ciapier C.R., Straub Π’., Papamarcaki Π’. Parathymosin affects the binding of linker histone HI to nucleosomes and remodels chromatin structure.// J. Biol. Chem. 2005 — V. 280 — P. 16 143−16 150.
- Mamoon N.M., Song Y. Wellman S.E. Binding of histone HI to DNA is described by an allosteric model.// Biopolymers. 2005 — V. 77 — P. 9−17.
- Catez F., Ueda T. Bustin M. Determinants of histone HI mobility and chromatin binding in living cells.// Nat. Struct. Mol. Biol. -2006 V. 13 — P. 305−310.
- Park YJ. Luger K. Histone chaperones in nucleosome eviction and histone exchange.// Curr. Opin. Struct. Biol. 2008 — V. 18 — P. 282−289.
- George E.M., Brown D.T. Prothymosin a is a component of a linker histone chaperone.// FEBS Letters. 2010 — V. 584 — P. 2833−2836.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.// Nature. 1970 — V. 227 — P. 680−685.
- ΠΡΡΡΡΠ½ΠΎΠ²Π° O.A., ΠΠ°Ρ Π°Π½ΠΎΠ² M., Π§Π΅Π½ΡΠ½ΠΊ A.A., Π§ΡΠΌΠ°ΠΊΠΎΠ² Π. Π., Π€ΡΠΎΠ»ΠΎΠ²Π° Π. Π. ΠΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎΠ»Π½ΠΎΠ³Π΅Π½ΠΎΠΌΠ½ΠΎΠΉ Π½Π΅ΡΠΏΠΎΡΡΠ΄ΠΎΡΠ΅Π½Π½ΠΎΠΉ ΠΊΠ»ΠΎΠ½ΠΎΡΠ΅ΠΊΠΈ ΠΊΠΎΡΠΎΡΠΊΠΈΡ ΡΠΏΠΈΠ»Π΅ΡΠ½ΡΡ Π ΠΠ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π»Π΅Π½ΡΠΈΠ²Π΅ΠΊΡΠΎΡΠ°.// ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ. 2006 — V. 40 — Π . 448−459.
- Chichkova N.V., Evstafieva A.G., Lyakhov I.G., Tsvetkov A.S., Smirnova T.A., Karapetian R.N., Karger E.M., Vartapetian A.B. Divalent metal cation binding properties of human prothymosin cc.// Eur. J. Biochem. 2000 — V. 267 — P. 4745−4752.
- Cai J.H., Deng S., Kumpf S.W., Lee P.A., Zagouras P., Ryan A., Gallagher D.S. Validation of rat reference genes for improved quantitative gene expression analysis' using low density arrays.// Biotechniques. 2007 — V. 42(4) — P. 503−512.
- Kobayashi Π’., Wang Π’., Maezawa M., Kobayashi M., Ohnishi S., Hatanaka K., Hige S., Shimizu Y., Kato M., Asaka M., Tanaka J., Imamura M., Hasegawa K., Tanaka Y.,
- Brachmann R.K. Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation.// Cancer Res. 2006 — V. 66 — P. 3137−3144.
- Shiau A.L., Lin P.R., Chang M.Y., Wu C.L. Retrovirus-mediated transfer of prothymosin gene inhibits tumor growth and prolongs survival in murine bladder cancer.// Gene Ther. — 2001 V. 8(21) — P. 1609−1617.1. ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΠΈ
- ΠΡΡΠ°ΠΆΠ°Ρ ΠΈΡΠΊΡΠ΅Π½Π½ΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ ΡΠ²ΠΎΠ΅ΠΌΡ Π½Π°ΡΡΠ½ΠΎΠΌΡ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΠ΅ ΠΠ΅ΠΎΡΠ³ΠΈΠ΅Π²Π½Π΅ ΠΠ²ΡΡΠ°ΡΡΠ΅Π²ΠΎΠΉ Π·Π° ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ ΡΠ°Π±ΠΎΡΡ, Π³ΡΠ°ΠΌΠΎΡΠ½ΠΎΠ΅ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΈ Π²ΡΠ΅ΡΡΠΎΡΠΎΠ½Π½ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ.
- Π₯ΠΎΡΠ΅ΡΡΡ Π²ΡΡΠ°Π·ΠΈΡΡ Π³Π»ΡΠ±ΠΎΠΊΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ ΠΌΠΎΠΈΠΌ ΠΊΠΎΠ»Π»Π΅Π³Π°ΠΌ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ Π² Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅: Π‘ΡΠ²ΠΎΡΠΎΠ²ΠΎΠΉ Π., Π‘ΠΎΠΊΠΎΠ»ΠΎΠ²Ρ Π., Π ΡΠ΄ΡΠΊΠΎ Π.
- ΠΡΠΊΡΠ΅Π½Π½Π΅ ΠΏΡΠΈΠ·Π½Π°ΡΠ΅Π»ΡΠ½Π° ΡΠ²ΠΎΠΈΠΌ ΡΡΠΈΡΠ΅Π»ΡΠΌ Π€Π°ΡΠ΅Π΅Π²ΠΎΠΉ Π’., ΠΠ΅Π»ΡΠ½ΠΈΠΊΠΎΠ²Ρ Π‘., Π€ΠΈΠ»ΠΎΠ½ΠΎΠ²Ρ Π. Π·Π° ΠΎΠ±ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ, ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈ Π²ΡΠ΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ ΠΏΠΎΠΌΠΎΡΡ Π² Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΈ Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ ΡΠ°Π±ΠΎΡΡ.
- ΠΡΡΠ°ΠΆΠ°Ρ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ Π₯ΡΡΠΎΡΠ½Π΅Π½ΠΊΠΎ Π., Π’ΡΠΆΠΈΠΊΠΎΠ²Ρ Π., Π’ΡΡΡΠΎΠ²ΠΎΠΉ Π‘. -ΡΠΎΡΡΡΠ΄Π½ΠΈΠΊΠ°ΠΌ Π½Π°ΡΠ΅ΠΉ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΈ — Π·Π° ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ², ΡΠ΅Π½Π½ΡΠ΅ ΡΠΎΠ²Π΅ΡΡ ΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ.
- ΠΡΠ΄Π΅Π»ΡΠ½Π°Ρ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ Π. Π. Π’Π΅ΡΠ΅Π½ΠΈΠ½Ρ Π·Π° ΠΏΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ Π΄ΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΠ½Π΄ΡΠ΅Π΅Π²Ρ Π. Π. ΠΈ ΠΠΌΠΈΡΡΠΈΠ΅Π²Ρ Π‘. Π. Π·Π° ΡΠ΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ ΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΡ Π½Π°ΡΡΠ½ΠΎΠΉ Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ.
- Π ΡΡΠ° ΡΠ°Π±ΠΎΡΠ° Π½Π΅ Π±ΡΠ»Π° Π±Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½Π° Π±Π΅Π· Π½Π΅ΠΎΡΠ΅Π½ΠΈΠΌΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ²Π°.